STY12, a Novel NQO1/HDAC Dual-Targeting Agent, Exhibits Potent Anti-Pancreatic Cancer Activity by ROS-Mediated DNA Damage
Biomolecules · 30.05.2026 · 16 (6) · 812
DOI: 10.3390/biom16060812 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 30.05.2026. Verfasst von Tong Shen und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Henan Medical University, Xinxiang 453003, China. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Pancreatic Neoplasms, DNA Damage, NAD(P)H Dehydrogenase (Quinone). Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Academy of Sciences, Natural Science Foundation of Henan, Xinxiang Medical University.
Abstract (Originalsprache)
Pancreatic cancer (PC) usually results in poor survival with limited treatment options. Reactive oxygen species (ROS) play a key role in the action of HDAC inhibitors. In combination with a ROS generator, it can increase sensitivity to HDAC inhibitors and also overcome resistance to HDAC inhibitors. NQO1-bioactivatable drugs are efficient ROS generators. Therefore, to reduce HDAC inhibitor resistance and enhance its anti-pancreatic cancer activity, in this study, we reported a novel NQO1/HDAC dual-targeting agent, STY12, which exhibited potent anti-pancreatic cancer activity through ROS-mediated DNA damage. STY12 strongly inhibited HDAC1 and HDAC6 activity (IC50 = 29 nM and 10 nM, respectively) and exhibited excellent reduction rates by NQO1 (kcat/Km = 5.59 × 106 M−1s−1). STY12 showed good anti-proliferative effects on PC MIA PaCa-2, SW1990, and Capan-2 cells, with IC50 values of 0.23 ± 0.01, 0.25 ± 0.01 and 0.14 ± 0.02 μM, respectively, and lower anti-proliferative effects against normal hTERT-HPNE and BEAS-2B cells. Mechanistic analysis revealed that STY12 suppressed the proliferation of MIA PaCa-2 cells by increasing the acetylation of histone 3 (H3) and α-tubulin, and increasing ROS-mediated DNA damage. Moreover, STY12 arrested the cell cycle at the S phase, inhibited the metastasis of MIA PaCa-2 cells, and promoted their apoptosis. Moreover, compared to SAHA and β-Lap, STY12 exhibited prominent in vivo antitumor activity with negligible toxic effects. Therefore, STY12 can serve as an effective NQO1/HDAC dual-targeting agent for the treatment of PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Henan Medical University, Xinxiang 453003, China.
- School of Pharmacy, Xinxiang University, Xinxiang 453003, China.
- West China School of Medicine, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Yanjie Dong
Förderung
- Henan Academy of Sciences
- Natural Science Foundation of Henan
- Xinxiang Medical University
Zitieren
APA
Shen, T., Yang, X., Han, Z., Dong, Y., & Wu, L. (2026). STY12, a Novel NQO1/HDAC Dual-Targeting Agent, Exhibits Potent Anti-Pancreatic Cancer Activity by ROS-Mediated DNA Damage. Biomolecules, 16(6), 812. https://doi.org/10.3390/biom16060812
Vancouver
Shen T, Yang X, Han Z, Dong Y, Wu L. STY12, a Novel NQO1/HDAC Dual-Targeting Agent, Exhibits Potent Anti-Pancreatic Cancer Activity by ROS-Mediated DNA Damage. Biomolecules. 2026;16(6):812. doi:10.3390/biom16060812
BibTeX
@article{Shen2026,
author = {Shen, Tong and Yang, Xiaojuan and Han, Zhenhua and Dong, Yanjie and Wu, Liqiang},
title = {STY12, a Novel NQO1/HDAC Dual-Targeting Agent, Exhibits Potent Anti-Pancreatic Cancer Activity by ROS-Mediated DNA Damage},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {6},
pages = {812},
doi = {10.3390/biom16060812}
}
EUVIMED